Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10472-10486

  Awasthi, Sita ^a   Lubinski, John M ^a   Shaw, Carolyn E ^a   Barrett, Shana M ^a   Cai, Michael ^a   Wang, Fushan ^a   Betts, Michael ^a   Kingsley, Susan ^b   DiStefano, Daniel J ^b   Balliet, John W ^b   Flynn, Jessica A ^b   Casimiro, Danilo R ^b   Bryan, Janine T ^b   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; GLYCOPROTEIN D; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; GUINEA PIG; HERPES SIMPLEX VIRUS 2; IMMUNE EVASION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SPINAL GANGLION; SURVIVAL RATE; VAGINA DISEASE; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GANGLIA, SPINAL; GUINEA PIGS; HERPES GENITALIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 2, HUMAN; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECURRENCE; VAGINA; VIRAL ENVELOPE PROTEINS; VIRUS SHEDDING;

ANIMALIA; CAVIA; HUMAN HERPESVIRUS 2; MUS;

EID: 80054987694     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00849-11     Document Type: Article

References (65)

1. Awasthi, S., J. M. Lubinski, and H. M. Friedman. 2009. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 27:6845-6853.
2. Betts, M. R., et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
3. Brittle, E. E., F. Wang, J. M. Lubinski, R. M. Bunte, and H. M. Friedman. 2008. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J. Virol. 82:8431-8441.
4. Bryson, Y. J., et al. 1983. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. 308:916-921.
5. Byars, N. E., et al. 1994. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 12:200-209.
6. Canziani, G., et al. 1999. Exploring biomolecular recognition using optical biosensors. Methods 19:253-269.
7. Carroll, M. C. 2004. The complement system in B cell regulation. Mol. Immunol. 41:141-146.
8. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986.
9. Chang, Y. J., M. Jiang, J. M. Lubinski, R. D. King, and H. M. Friedman. 2005. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains. Vaccine 23:4658-4665.
10. Chung, K. M., et al. 2006. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc. Natl. Acad. Sci. U. S. A. 103:19111-19116.
11. Cohen, J. 2010. Painful failure of promising genital herpes vaccine. Science 330:304.
12. Corey, L., et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282: 331-340.
13. Da Costa, X. J., L. A. Morrison, and D. M. Knipe. 2001. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 288:256-263.
14. Darrah, P. A., et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
15. Dubin, G., E. Socolof, I. Frank, and H. M. Friedman. 1991. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65:7046-7050.
16. Fang, C., T. Miwa, H. Shen, and W. C. Song. 2007. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J. Immunol. 179: 3178-3186.
17. Frank, I., and H. M. Friedman. 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol. 63:4479-4488.
18. Friedman, H. M. 2000. Immunologic strategies for herpes vaccination. JAMA 283:746.
19. Friedman, H. M., G. H. Cohen, R. J. Eisenberg, C. A. Seidel, and D. B. Cines. 1984. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309:633-635.
20. Girgis, N. M., et al. 2008. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J. Virol. 82: 4205-4214.
21. Gupta, R., T. Warren, and A. Wald. 2007. Genital herpes. Lancet 370:2127-2137.
22. Hook, L. M., J. M. Lubinski, M. Jiang, M. K. Pangburn, and H. M. Friedman. 2006. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. J. Virol. 80:4038-4046.
23. Hoshino, Y., et al. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 200: 1088-1095.
24. Huemer, H. P., C. Larcher, S. van Drunen Littel-van den Hurk, and L. A. Babiuk. 1993. Species selective interaction of Alphaherpesvirinae with the "unspecific" immune system of the host. Arch. Virol. 130:353-364.
25. Hung, S. L., et al. 1994. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 203:299-312.
26. Jarva, H., S. Ram, U. Vogel, A. M. Blom, and S. Meri. 2005. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 174:6299-6307.
27. Johansson, P. J., E. B. Myhre, and J. Blomberg. 1985. Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulin G from different animal species. J. Virol. 56:489-494.
28. + T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 82:9678-9688.
29. Judson, K. A., et al. 2003. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J. Virol. 77: 12639-12645.
30. Kapadia, S. B., B. Levine, S. H. Speck, and H. W. T. Virgin. 2002. Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. Immunity 17:143-155.
31. Kapadia, S. B., H. Molina, V. van Berkel, S. H. Speck, and H. W. T. Virgin. 1999. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73:7658-7670.
32. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
33. Koelle, D. M., et al. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1500-1508.
34. Kopf, M., B. Abel, A. Gallimore, M. Carroll, and M. F. Bachmann. 2002. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 8:373-378.
35. Lachmann, P. J., and A. Davies. 1997. Complement and immunity to viruses. Immunol. Rev. 159:69-77.
36. Lekstrom-Himes, J. A., L. Pesnicak, and S. E. Straus. 1998. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J. Virol. 72: 2760-2764.
37. Lilley, B. N., H. L. Ploegh, and R. S. Tirabassi. 2001. Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J. Virol. 75:11218-11221.
38. Litwin, V., W. Jackson, and C. Grose. 1992. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J. Virol. 66:3643-3651.
39. Lubinski, J. M., H. M. Lazear, S. Awasthi, F. Wang, and H. M. Friedman. 2011. The herpes simplex virus 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol. 85:3239-3249.
40. Lubinski, J. M., et al. 1998. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72:8257-8263.
41. Madico, G., et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
42. Magaret, A. S., A. Wald, M. L. Huang, S. Selke, and L. Corey. 2007. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J. Clin. Microbiol. 45:1618-1620.
43. Mehlhop, E., and M. S. Diamond. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
44. Meignier, B., B. Martin, R. J. Whitley, and B. Roizman. 1990. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162:313-321.
45. Milligan, G. N., and D. I. Bernstein. 1995. Analysis of herpes simplex virusspecific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology 212:481-489.
46. Nagashunmugam, T., et al. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72: 5351-5359.
47. Nass, P. H., K. L. Elkins, and J. P. Weir. 2001. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 19:1538-1546.
48. Ngampasutadol, J., et al. 2005. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc. Natl. Acad. Sci. U. S. A. 102:17142-17147.
49. Ngampasutadol, J., et al. 2008. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J. Immunol. 180:3426-3435.
50. Para, M. F., L. Goldstein, and P. G. Spear. 1982. Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J. Virol. 41:137-144.
51. Phipps, W., et al. 2011. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J. Infect. Dis. 203:180-187.
52. Renzi, C., et al. 2003. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J. Infect. Dis. 187:19-25.
53. Reynolds, S. J., et al. 2003. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J. Infect. Dis. 187:1513-1521.
54. Sawtell, N. M., D. I. Bernstein, and L. R. Stanberry. 1999. A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 in vivo reactivation in the mouse trigeminal ganglia. J. Infect. Dis. 180:821-823.
55. Sawtell, N. M., R. L. Thompson, L. R. Stanberry, and D. I. Bernstein. 2001. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J. Infect. Dis. 184:964-971.
56. Seidel-Dugan, C., et al. 1988. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J. Virol. 62:4027-4036.
57. Stanberry, L. R., et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
58. Strainic, M. G., et al. 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:425-435.
59. Tal-Singer, R., et al. 1995. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J. Virol. 69:4471-4483.
60. Tengvall, S., A. Lundqvist, R. J. Eisenberg, G. H. Cohen, and A. M. Harandi. 2006. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80:5283-5291.
61. Thompson, R. L., and N. M. Sawtell. 2001. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J. Virol. 75: 6660-6675.
62. Van de Walle, G. R., H. W. Favoreel, H. J. Nauwynck, and M. B. Pensaert. 2003. Antibody-induced internalization of viral glycoproteins and gE-gI Fc receptor activity protect pseudorabies virus-infected monocytes from efficient complement-mediated lysis. J. Gen. Virol. 84:939-947.
63. Wald, A., and K. Link. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185:45-52.
64. Xiao, Y., et al. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25:1214-1224.
65. Zhang, J., et al. 2009. Influenza A virus M1 blocks the classical complement pathway through interacting with C1qA. J. Gen. Virol. 90:2751-2758.